DKTK-Studienregister

DetailsucheDetailsuche
Klicken Sie auf Detailsuche, um z.B. nach Therapielinie, molekularem Marker oder Rekrutierungsstatus zu suchen.
FreitextsucheFreitextsuche
Sie können hier nach dem Studienkurzcode oder einem Teil des Studientitels suchen.
Studienauswahl
Zentren
Status der Studie

» Urogenitale Tumoren » Nierenzellkarzinom

Alle Linien

Bayer 19131
Phase 1b/2 study of rogaratinib (BAY 1163877) in combination with atezolizumab in urothelial carcinoma (Aktiv)

FAMIAN-Study
Das Ziel der FAMIAN-Studie ist es, unklare Nebennierentumoren durch eine nicht-invasive und damit patientenfreundlichere diagnostische Methode genauer zu charakterisieren. (Aktiv)

SUNNIFORECAST
Randomized Phase-II Study of Nivolumab Plus Ipilimumab vs. Standard of Care in Untreated and Advanced Non-clear Cell RCC (Aktiv)

UC02-PSMA-01
Dose-escalating Trial With UniCAR02-T Cells and PSMA Target Module (TMpPSMA) in Patients With Progressive Disease After Standard Systemic Therapy in Cancers With Positive PSMA Marker (Aktiv)

Erstlinie

ATEZOLIZUMAB RCC
A PHASE III STUDY OF ATEZOLIZUMAB (Anti-PD-L1 ANTIBODY) IN COMBINATION WITH BEVACIZUMAB VERSUS SUNITINIB (Aktiv)

BP39365
This is an open-label, multi-center, randomized, Phase 1b, adaptive, clinical study to assess the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary therapeutic activity of RO6874281 in combination with atezolizumab with/without bevacizumab in participants with unresectable advanced and/or metastatic RCC. The study will consist of a dose-escalation part and an extension part (Aktiv)

FIRST-MAPPP
First International Randomized Study in Malignant Progressive Pheochromocytoma and Paraganglioma (Aktiv)

MK-3475-905
Randomisierte Phase-3-Studie zur Bewertung der Zystektomie mit perioperativer Pembrolizumab und Zystektomie mit perioperativem Enfortumab Vedotin und Pembrolizumab versus Zystektomie allein bei Cisplatin-ineligiblen Teilnehmern mit muskelinvasiver Blase Krebs (KEYNOTE-905/EV-303) (Aktiv)

Zweitlinie oder später

ADIUVO
Wirksamkeit einer adjuvanten Mitotane-Behandlung bei Patienten mit Nebennierenkarzinom (Aktiv)

CNIR178X2201
Study of efficacy and safety of NIR178 and PDR001 combination in patients with selected solid tumors and non-Hodgkin lymphoma (Aktiv)

CVPM087A2101
Gevokizumab With Standard of Care Anti-cancer Therapies for Metastatic Colorectal, Gastroesophageal, and Renal Cancers (Aktiv)

CaboPoint (Ipsen)
Study of Cabozantinib as 2nd Line Treatment in Subjects With Locally Advanced or Metastatic Renal Cell Carcinoma (RCC) With a Clear-Cell Component Who Progressed After 1st Line Treatment With Checkpoint Inhibitors (Aktiv)

GEM3PSCA-01
Study With Bispecific Antibody Engaging T-cells, in Patients With Progressive Cancer Diseases With Positive PSCA Marker (Aktiv)

GO39733
This is a Phase 1a/1b, open-label, multicenter, global, dose-escalation study designed to evaluate the safety, tolerability, immune response, and pharmacokinetics of RO7198457 as a single agent and in combination with atezolizumab (MPDL3280A, an engineered anti-programmed death-ligand 1 [anti-PD-L1] antibody). (Aktiv)

IO-PAZ
Study of efficacy and safety of pazopanib in patients with advanced and/or metastatic renal cell carcinoma after prior checkpoint inhibitor treatment (Aktiv)

DKTK-Studienregister
Dr. N. Gökbuget, Dipl.-Biol. K. Ihrig | Ohne Gewähr für Richtigkeit oder Vollständigkeit | ccp@dkfz.de